Zhitong Finance App News, Laikai Pharmaceutical-B (02105.HK) announced that the Group has completed the LAE102 24-week single-drug treatment study for the low dose group treatment. This data is consistent with LAE102's previous single dose escalation (SAD) and multiple dose escalation (MAD) studies, showing positive changes in body composition. Of particular note, the completed low dose group showed encouraging weight loss results, with muscle gain and fat loss observed. The 24-week treatment was well tolerated. No serious adverse events were reported, and no reports of diarrhea, muscle cramps, or acne were reported, which is consistent with the SAD and MAD findings previously disclosed.

Zhitong Finance App News, Laikai Pharmaceutical-B (02105.HK) announced that the Group has completed the LAE102 24-week single-drug treatment study for the low dose group treatment. This data is consistent with LAE102's previous single dose escalation (SAD) and multiple dose escalation (MAD) studies, showing positive changes in body composition. Of particular note, the completed low dose group showed encouraging weight loss results, with muscle gain and fat loss observed. The 24-week treatment was well tolerated. No serious adverse events were reported, and no reports of diarrhea, muscle cramps, or acne were reported, which is consistent with the SAD and MAD findings previously disclosed.